GSK
Price
$35.48
Change
-$0.88 (-2.42%)
Updated
Nov 12, 12:50 PM (EDT)
85 days until earnings call
MRK
Price
$100.73
Change
-$2.19 (-2.13%)
Updated
Nov 11 closing price
84 days until earnings call
Ad is loading...

GSK vs MRK

Header iconGSK vs MRK Comparison
Open Charts GSK vs MRKBanner chart's image
GSK
Price$35.48
Change-$0.88 (-2.42%)
Volume$2.33K
CapitalizationN/A
Merck & Co
Price$100.73
Change-$2.19 (-2.13%)
Volume$10.08M
CapitalizationN/A
GSK vs MRK Comparison Chart
Loading...
GSK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MRK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
GSK vs. MRK commentary
Nov 12, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a StrongSell and MRK is a StrongBuy.

COMPARISON
Comparison
Nov 12, 2024
Stock price -- (GSK: $36.35 vs. MRK: $100.73)
Brand notoriety: GSK: Not notable vs. MRK: Notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GSK: 88% vs. MRK: 102%
Market capitalization -- GSK: $88.13B vs. MRK: $331.75B
GSK [@Pharmaceuticals: Major] is valued at $88.13B. MRK’s [@Pharmaceuticals: Major] market capitalization is $331.75B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GSK’s FA Score shows that 2 FA rating(s) are green whileMRK’s FA Score has 2 green FA rating(s).

  • GSK’s FA Score: 2 green, 3 red.
  • MRK’s FA Score: 2 green, 3 red.
According to our system of comparison, both GSK and MRK are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GSK’s TA Score shows that 4 TA indicator(s) are bullish while MRK’s TA Score has 4 bullish TA indicator(s).

  • GSK’s TA Score: 4 bullish, 5 bearish.
  • MRK’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, MRK is a better buy in the short-term than GSK.

Price Growth

GSK (@Pharmaceuticals: Major) experienced а -1.68% price change this week, while MRK (@Pharmaceuticals: Major) price change was -1.12% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.36%. For the same industry, the average monthly price growth was -2.22%, and the average quarterly price growth was +6.05%.

Reported Earning Dates

GSK is expected to report earnings on Feb 05, 2025.

MRK is expected to report earnings on Feb 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-2.36% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRK($332B) has a higher market cap than GSK($88.1B). MRK has higher P/E ratio than GSK: MRK (935.64) vs GSK (14.01). GSK YTD gains are higher at: 0.804 vs. MRK (-5.836). GSK has higher annual earnings (EBITDA): 9.08B vs. MRK (6.91B). MRK has more cash in the bank: 7.09B vs. GSK (4.99B). GSK has less debt than MRK: GSK (18B) vs MRK (35.1B). MRK has higher revenues than GSK: MRK (60.1B) vs GSK (30.3B).
GSKMRKGSK / MRK
Capitalization88.1B332B27%
EBITDA9.08B6.91B132%
Gain YTD0.804-5.836-14%
P/E Ratio14.01935.641%
Revenue30.3B60.1B50%
Total Cash4.99B7.09B70%
Total Debt18B35.1B51%
FUNDAMENTALS RATINGS
GSK vs MRK: Fundamental Ratings
GSK
MRK
OUTLOOK RATING
1..100
454
VALUATION
overvalued / fair valued / undervalued
1..100
7
Undervalued
14
Undervalued
PROFIT vs RISK RATING
1..100
7934
SMR RATING
1..100
5028
PRICE GROWTH RATING
1..100
6362
P/E GROWTH RATING
1..100
898
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GSK's Valuation (7) in the Pharmaceuticals Major industry is in the same range as MRK (14). This means that GSK’s stock grew similarly to MRK’s over the last 12 months.

MRK's Profit vs Risk Rating (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for GSK (79). This means that MRK’s stock grew somewhat faster than GSK’s over the last 12 months.

MRK's SMR Rating (28) in the Pharmaceuticals Major industry is in the same range as GSK (50). This means that MRK’s stock grew similarly to GSK’s over the last 12 months.

MRK's Price Growth Rating (62) in the Pharmaceuticals Major industry is in the same range as GSK (63). This means that MRK’s stock grew similarly to GSK’s over the last 12 months.

GSK's P/E Growth Rating (8) in the Pharmaceuticals Major industry is significantly better than the same rating for MRK (98). This means that GSK’s stock grew significantly faster than MRK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GSKMRK
RSI
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
69%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
53%
Bullish Trend 1 day ago
56%
Momentum
ODDS (%)
Bearish Trend 1 day ago
58%
N/A
MACD
ODDS (%)
Bearish Trend 1 day ago
49%
Bearish Trend 1 day ago
45%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
50%
Bearish Trend 1 day ago
49%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
50%
Bearish Trend 1 day ago
43%
Advances
ODDS (%)
Bullish Trend 8 days ago
53%
Bullish Trend 5 days ago
48%
Declines
ODDS (%)
Bearish Trend 13 days ago
52%
Bearish Trend 7 days ago
48%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
63%
Bullish Trend 1 day ago
63%
Aroon
ODDS (%)
Bearish Trend 1 day ago
54%
Bearish Trend 1 day ago
43%
View a ticker or compare two or three
Ad is loading...
GSK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MRK
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WCN185.361.32
+0.72%
Waste Connections
AZUL2.67-0.01
-0.37%
Azul SA
MMI41.89-0.28
-0.66%
Marcus & Millichap
SSL5.56-0.17
-2.97%
Sasol Limited
GORO0.15-0.01
-4.81%
Gold Resource Corp

MRK and

Correlation & Price change

A.I.dvisor tells us that MRK and AZN have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MRK and AZN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRK
1D Price
Change %
MRK100%
-2.13%
AZN - MRK
29%
Poorly correlated
+0.42%
GSK - MRK
23%
Poorly correlated
+0.17%
JNJ - MRK
22%
Poorly correlated
-0.28%
SNY - MRK
22%
Poorly correlated
-1.38%
NVS - MRK
21%
Poorly correlated
-0.73%
More